B-intervention	0	4	High
I-intervention	4	5	-
I-intervention	5	9	dose
I-intervention	10	22	chemotherapy
O	23	27	with
O	28	42	haematopoietic
O	43	47	stem
O	48	52	cell
O	53	68	transplantation
O	69	72	for
O	73	83	metastatic
O	84	90	breast
O	91	97	cancer
O	98	106	patients
O	106	107	:
O	108	113	final
O	114	121	results
O	122	124	of
O	125	128	the
B-location	129	135	French
O	136	148	multicentric
O	149	159	randomised
O	160	163	CMA
O	163	164	/
O	164	170	PEGASE
O	171	173	04
O	174	182	protocol
O	182	183	.

O	184	187	The
O	188	191	aim
O	192	194	of
O	195	198	our
O	199	204	study
O	205	208	was
O	209	211	to
O	212	220	evaluate
O	221	224	the
O	225	231	impact
O	232	234	on
O	235	239	time
O	240	242	to
O	243	254	progression
O	255	256	(
O	256	259	TTP
O	259	260	)
O	261	264	and
O	265	272	overall
O	273	281	survival
O	282	283	(
O	283	285	OS
O	285	286	)
O	287	289	of
O	290	294	high
O	294	295	-
O	295	299	dose
O	300	312	chemotherapy
O	313	314	(
O	314	316	HD
O	316	317	-
O	317	319	CT
O	319	320	)
O	321	325	over
B-control	326	338	conventional
I-control	339	341	CT
O	342	344	in
B-eligibility	345	355	metastatic
I-eligibility	356	362	breast
I-eligibility	363	369	cancer
I-eligibility	370	378	patients
O	378	379	.

O	380	387	Between
O	388	390	09
O	390	391	/
O	391	393	92
O	394	397	and
O	398	400	12
O	400	401	/
O	401	403	96
O	403	404	,
B-total-participants	405	407	61
B-eligibility	408	416	patients
I-eligibility	417	421	with
I-eligibility	422	436	chemosensitive
I-eligibility	437	447	metastatic
I-eligibility	448	454	breast
I-eligibility	455	461	cancer
O	462	466	were
O	467	477	randomised
O	478	485	between
O	486	488	HD
O	488	489	-
O	489	491	CT
O	492	497	using
O	498	501	the
O	502	505	CMA
O	506	513	regimen
O	514	515	(
O	515	527	Mitoxantrone
O	527	528	,
O	529	545	Cyclophosphamide
O	545	546	,
O	547	556	Melphalan
O	556	557	)
O	558	565	applied
O	566	568	as
O	569	582	consolidation
O	583	584	(
B-intervention-participants	584	586	32
O	587	595	patients
O	595	596	)
O	597	599	or
O	600	611	maintenance
O	612	614	CT
O	615	616	(
B-control-participants	616	618	29
O	619	627	patients
O	627	628	)
O	628	629	.

O	630	632	At
O	633	646	randomisation
O	646	647	,
O	648	650	13
O	651	659	patients
O	660	664	were
O	665	667	in
B-outcome	668	676	complete
I-outcome	677	685	response
O	685	686	,
O	687	689	47
O	690	692	in
B-outcome	693	700	partial
I-outcome	701	709	response
O	710	713	and
O	714	717	one
O	718	721	had
B-outcome	722	728	stable
I-outcome	729	736	disease
O	736	737	.

O	738	741	The
B-outcome	742	748	median
I-outcome	749	753	TTPs
O	754	758	from
O	759	772	randomisation
O	773	777	were
B-iv-cont-median	778	779	6
O	780	783	and
B-cv-cont-median	784	786	12
I-cv-cont-median	787	793	months
O	794	796	in
O	797	800	the
O	801	809	standard
O	810	813	and
O	814	823	intensive
O	824	830	groups
O	830	831	,
O	832	844	respectively
O	845	846	(
O	846	847	P
O	848	849	<
O	850	851	0
O	851	852	.
O	852	856	0056
O	856	857	)
O	857	858	,
O	859	863	with
O	864	865	a
B-outcome	866	873	relapse
I-outcome	874	878	rate
O	879	881	of
B-iv-bin-percent	882	884	86
I-iv-bin-percent	884	885	.
I-iv-bin-percent	885	886	2
I-iv-bin-percent	886	887	%
O	888	890	vs
O	890	891	.
B-cv-bin-percent	892	894	62
I-cv-bin-percent	894	895	.
I-cv-bin-percent	895	896	5
I-cv-bin-percent	896	897	%
B-outcome	898	900	at
I-outcome	901	902	2
I-outcome	903	908	years
O	908	909	,
O	910	913	and
B-iv-bin-percent	914	917	100
I-iv-bin-percent	917	918	%
O	919	921	vs
O	921	922	.
B-cv-bin-percent	923	925	81
I-cv-bin-percent	925	926	.
I-cv-bin-percent	926	927	3
I-cv-bin-percent	927	928	%
B-outcome	929	931	at
I-outcome	932	933	5
I-outcome	934	939	years
O	939	940	.

O	941	944	The
B-outcome	945	951	median
I-outcome	952	954	OS
I-outcome	955	960	times
O	961	965	were
B-iv-cont-median	966	968	19
I-iv-cont-median	968	969	.
I-iv-cont-median	969	970	3
O	971	974	and
B-cv-cont-median	975	977	44
I-cv-cont-median	977	978	.
I-cv-cont-median	978	979	1
I-cv-cont-median	980	986	months
O	986	987	,
O	988	992	with
O	993	995	an
B-outcome	996	998	OS
I-outcome	999	1003	rate
O	1004	1006	of
B-iv-bin-percent	1007	1009	13
I-iv-bin-percent	1009	1010	.
I-iv-bin-percent	1010	1011	8
I-iv-bin-percent	1011	1012	%
O	1013	1015	vs
O	1015	1016	.
B-cv-bin-percent	1017	1019	36
I-cv-bin-percent	1019	1020	.
I-cv-bin-percent	1020	1021	8
I-cv-bin-percent	1021	1022	%
B-outcome	1023	1025	at
I-outcome	1026	1027	5
I-outcome	1028	1033	years
O	1034	1035	(
O	1035	1036	P
O	1037	1038	<
O	1039	1040	0
O	1040	1041	.
O	1041	1045	0294
O	1045	1046	)
O	1046	1047	.

O	1048	1051	The
O	1052	1055	CMA
O	1056	1063	regimen
O	1064	1069	could
O	1070	1077	prolong
O	1078	1081	the
O	1082	1085	TTP
O	1086	1088	of
O	1089	1097	patients
O	1098	1102	with
O	1103	1117	chemosensitive
O	1118	1128	metastatic
O	1129	1135	breast
O	1136	1142	cancer
O	1142	1143	.

O	1144	1151	Further
O	1152	1159	studies
O	1160	1163	are
O	1164	1170	needed
O	1171	1173	to
O	1174	1183	determine
O	1184	1186	if
O	1187	1191	this
O	1192	1202	translates
O	1203	1207	into
O	1208	1210	an
O	1211	1217	effect
O	1218	1220	on
O	1221	1223	OS
O	1223	1224	.
